Amneal Pharmaceuticals Receives FDA Approval For New Potassium Phosphates IV Infusion Bag; First Preservative-Free Single-Dose Presentation; Third 505(b)(2) Injectable Added This Year, Launching In Q3
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals has received FDA approval for its new Potassium Phosphates IV Infusion Bag, which is the first preservative-free single-dose presentation. This is the third 505(b)(2) injectable added by the company this year, and it will be launched in Q3.
July 29, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amneal Pharmaceuticals has received FDA approval for its new Potassium Phosphates IV Infusion Bag, marking the third 505(b)(2) injectable added this year. The product will launch in Q3.
The FDA approval of a new product typically has a positive impact on a pharmaceutical company's stock price. This approval adds to Amneal's portfolio of 505(b)(2) injectables, indicating growth and potential revenue increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100